Organization
Anhui Provincal Hospital
2 abstracts
Abstract
First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors.Org: ChangSha TaiHe Hospital, Shulan (Hangzhou) Hospital, Deyang People's Hospital, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Anhui Provincal Hospital,
Abstract
BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.Org: Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Third Hospital of Nanchang,